Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 16/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15583861 | 0.83 | HPGD (0.68) | XDHADORA1ADORA2AHSD17B10ALDH1A1 | |
| SCHEMBL23851982 | 0.81 | HPGD (0.58) | XDHADORA1ADORA2AHSD17B10ALDH1A1 | |
| SCHEMBL2572687 | 0.81 | XDH (1.00) | XDHADORA1ADORA2AALDH1A1KDM4E | |
| SCHEMBL6440926 | 0.77 | ADORA2A (0.54) | XDHADORA1ADORA2AHSD17B10ALDH1A1 | |
| SCHEMBL6440910 | 0.74 | ADORA1 (1.00) | ADORA1ADORA2AADORA2B | |
| SCHEMBL18153594 | 0.72 | HPGD (0.47) | XDHADORA1ADORA2AHSD17B10ALDH1A1 | |
| SCHEMBL935141 | 0.71 | ALDH1A1 (1.00) | ADORA1ADORA2AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL5157870 | 0.70 | XDH (0.59) | XDHADORA1ADORA2AHSD17B10ALDH1A1 | |
| SCHEMBL1145014 | 0.69 | ADORA1 (0.64) | XDHADORA1ADORA2AHSD17B10ADORA2B | |
| SCHEMBL15840888 | 0.69 | ADORA1 (0.64) | XDHADORA1ADORA2AHSD17B10ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1675861-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| EP-1261327-B1 | ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005021552-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2005-03-10 | — | — | WO | disclosed |
| US-6586441-B2 | 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders | HOFFMAN-LA ROCHE INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120767-A1 | Pyrimidothiophene Compounds | ALK, HSP90AA1, HSP90AB1 | XDH 3262/4885ADORA1 484/4885ADORA2A 999/4885 |
| US-20070043044-A1 | Pyrimidothiophene compounds | ALK, HSP90AA1, HSP90AB1 | XDH 3485/4885ADORA1 565/4885ADORA2A 1224/4885 |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | XDH 698/4885ADORA1 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.